Current pharmacotherapy for the treatment of severe burns

Expert Opinion on Pharmacotherapy

Volumn 4, Issue 3, 2003, Pages 369-384

  Murphy, Kevin D ^a   Lee, Jong O ^a   Herndon, David N ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

Author keywords

Antibiotics; Burns; Pharmacotherapy; Sepsis

Indexed keywords

ADRENERGIC RECEPTOR BLOCKING AGENT; ALFENTANIL; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; ANALGESIC AGENT; ANTIBIOTIC AGENT; BENZODIAZEPINE; CATECHOLAMINE; CLONIDINE; FENTANYL CITRATE; GLUCAGON; GROWTH HORMONE; HYDROCORTISONE; IMMUNOMODULATING AGENT; INSULIN; LAXATIVE; MAFENIDE; MAFENIDE ACETATE; MORPHINE; MU OPIATE RECEPTOR AGONIST; NITROUS OXIDE; NITROUS OXIDE PLUS OXYGEN; OPIATE; OXANDROLONE; OXYCODONE; PROPRANOLOL; PROSTAGLANDIN; REMIFENTANIL; SEDATIVE AGENT; SILVER NITRATE; STEROID; SULFADIAZINE SILVER; UNINDEXED DRUG;

ACUTE STRESS DISORDER; AMNION; ANALGESIA; ANTIBIOTIC RESISTANCE; ANXIETY DISORDER; BACTERIAL INFECTION; BONE MINERALIZATION; BREATHING DISORDER; BURN; BURN DRESSING; CADAVER DONOR; CATABOLISM; CATECHOLAMINE BLOOD LEVEL; CLINICAL TRIAL; DEBRIDEMENT; DEEP VEIN THROMBOSIS; DEPRESSION; DISEASE ASSOCIATION; DISEASE SEVERITY; ENERGY EXPENDITURE; GASTROINTESTINAL DISEASE; GLUCAGON BLOOD LEVEL; HEART DISEASE; HOSPITAL INFECTION; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYPERMETABOLISM; HYPOTENSION; IMMUNE DEFICIENCY; INFECTION CONTROL; LIPOLYSIS; LUNG BURN; NAUSEA AND VOMITING; OPPORTUNISTIC INFECTION; PALLIATIVE THERAPY; PEPTIC ULCER; POSTTRAUMATIC STRESS DISORDER; PROSTAGLANDIN BLOOD LEVEL; PRURITUS; PSYCHOSOCIAL DISORDER; REVIEW; SEDATION; SKELETAL MUSCLE; SKIN AUTOGRAFT; SURVIVAL; TREATMENT OUTCOME; WOUND CARE; WOUND INFECTION;

ADMINISTRATION, TOPICAL; ANALGESICS; ANIMALS; ANTI-ANXIETY AGENTS; ANTI-BACTERIAL AGENTS; ANTIEMETICS; BURNS; HUMANS; HYPNOTICS AND SEDATIVES; MINERALS; PEPTIC ULCER; PRURITUS; PULMONARY EMBOLISM; VENOUS THROMBOSIS; VITAMINS;

EID: 0037348699     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.4.3.369     Document Type: Review

References (115)

1. PRUITT BA, GOODWIN CW, MASON AD Jr: Epidemiological, demographic and outcome characteristics of burn injury. In: Total Burn Care. 2nd Edn. Herndon DN (Ed.) WB Saunders, Philadelphia, PA, USA (2002):16.
2. MUNSTER AM: Burns in India. J. Burn Care Rehabil. (1994) 15(3):260-268.
3. RAJPURA A: The epidemiology of burns and smoke inhalation in secondary care: a population-based study covering Lancashire and South Cambria. Burns (2002) 28(2):121-130.
4. LINARES AZ, LINARES HA: Burn prevention: the need for a comprehensive approach. Burns (1990) 16(4):281-285.
5. SHERIDAN RL, REMENSNYDER JP, SCHNITZER JJ, SCHULZ JT, RYAN CM, TOMPKINS RG: Current expectations for survival in pediatric burns. Arch. Pediatr. Adolesc. Med. (2000) 154(3):245-249.
6. RASHID A, KHANNA A, GOWAR JP, BULL JP: Revised estimates of mortality from burns in the last 20 years at the Birmingham Burns Centre. Burns (2001) 27(7):723-730.
7. HERNDON DN: Total Burn Care. 2nd Edn. WB Saunders, Philadelphia, PA, USA (2002):5.
8. FOX CL Jr: Silver sulphadiazine - a new topical therapy for Pseudomonas in burns. Therapy of Pseudomonas infection in burns. Arch. Surg. (1968) 96(2):184-188.
9. GALLAGHER G, RAE CP, KINSELLA J: Treatment of pain in severe burns. Am. J. Clin. Dermatol. (2000) 1(6):329-335.
10. PAL SK, CORTIELLA J, HERNDON DN: Adjunctive methods of pain control in burns. Burns (1997) 23(5):404-412.
11. RAJA SN, CAMPBELL JN, MEYER RA: Evidence for different mechanisms of primary and secondary hyperalgesia following heat injury to the glabrous skin. Brain (1984) 107(Pt 4):1179-1188.
12. APRILE AE: Complex regional pain syndrome. AANA J. (1997) 65(6):557-560.
13. STANTON-HICKS M: Reflex sympathetic dystrophy: a sympathetically mediated pain syndrome or not? Curr. Rev. Pain (2000) 4(4):268-275.
14. LYONS B, CASEY W, DOHERTY P, MCHUGH M, MOORE KP: Pain relief with low-dose intravenous clonidine in a child with severe burns. Intensive Care Med. (1996) 22(3):249-251.
15. MARINANGELI F, CICCOZZI A, DONATELLI F et al.: Clonidine for treatment of postoperative pain: a dose-finding study. Eur. J. Pain (2002) 6(1):35-42.
16. SAXE G, STODDARD F, COURTNEY D et al.: Relationship between acute morphine and the course of PTSD in children with burns. J. Am. Acad. Child Adolesc. Psychiatry (2001) 40(8):915-921.
17. SHARAR SR, BRATTON SL, CARROUGHER GJ et al.: A comparison of oral transmucosal fentanyl citrate and oral hydromorphone for inpatient pediatric burn wound care analgesia. J. Burn Care Rehabil. (1998) 19(6):516-521.
18. LINNEMAN PK, TERRY BE, BURD RS: The efficacy and safety of fentanyl for the management of severe procedural pain in patients with burn injuries. J. Burn Care Rehabil. (2000) 21(6):519-522.
19. SHARAR SR, BRATTON SL, CARROUGHER GJ et al.: A comparison of oral transmucosal fentanyl citrate and oral hydromorphone for inpatient pediatric burn wound care analgesia. J. Burn Care Rehabil. (1998) 19:516-521.
20. LINNEMAN PK, TERRY BE, BURD RS: The efficacy and safety of fentanyl for the management of severe procedural pain in patients with burn injuries. J. Burn Care Rehabil. (2000) 21(6):519-522.
21. SIM KM, HWANG NC, CHAN YW. SEAH CS: Use of patient-controlled analgesia with alfentanil for burns dressing procedures: a preliminary report of five patients. Burns (1996) 22(3):238-241.
22. MEYER WJ 3rd, NICHOLS RJ, CORTIELLA J et al.: Acetaminophen in the management of background pain in children post-burn. J. Pain Symptom Manage. (1997) 13(1):50-55.
23. SINATRA R. Role of COX-2 inhibitors in the evolution of acute pain management. J. Pain Symptom Manage. (2002) 24(1 Suppl.):S18-S27.
24. SILVERSTEIN FE, FAICH G, GOLDSTEIN JL et al.: Gastrointestinal toxicity with celecoxib versus nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study. a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA (2000) 284(10):1247-1255.
25. WHELTON A, FORT JG, PUMA JA, NORMANDIN D, BELLO AE, VERBURG KM: Cyclooxygenase-2-specific inhibitors and cardiorenal function: a randomized, controlled trial of celecoxib and rofecoxib in older hypertensive ostecarthritis patients. Am. J. Ther. (2001) 8:85-95.
26. PFISTER AK, CRISALLT RJ, CARTER WH: Cyclooxygenase-2 inhibition and renal function. Ann. Intern. Med. (2001) 134(11):1077-1078.
27. LAFFI G, LA VILLA G, PINZANI M, MARRA F, GENTILINI P: Arachidonic acid derivatives and renal function in liver cirrhosis. Semin. Nephrol. (1997) 17(6):530.
28. SWAN SK, RUDY DW. LASSETER KC et al.: Effect of cyclooxygenase-2 inhibition on renal function in elderly persons receiving a low-salt diet. A randomized, controlled trial. Ann. Intern. Med. (2000) 133(1):1-9.
29. STOLTZ RR, HARRIS SI, KUSS ME et al: Upper GI mucosal effects of parecoxib sodium in healthy elderly subjects. Am. J. Gastroenterology (2002) 97(1):65-71.
30. ROVERS J, KNIGHTON J, NELIGAN P. PETERS W: Patient-controlled analgesia in burn patients: a critical review of the literature and case report. Hosp. Pharm. (1994) 29(2):106-111.
31. SIM KM, HWANG NC, CHAN YW, SEAH CS: Use of patient-controlled analgesia with alfentanil for burns dressing procedures: a preliminary report of five patients. Burns (1996) 22(3):238-241.
32. MCDONALD AJ, COOPER MG. Patient-controlled analgesia: an appropriate method of pain control in children. Paediatr. Drugs (2001) 3(4):273-284.
33. DICKINSON R, SINGER AJ, CARRION W. Etomidate for pediatric sedation prior to fracture reduction. Acad. Emerg. Med. (2001) 8(1):74-77.
34. HUMPHRIES Y. MELSON M, GORE D: Superiority of oral ketamine as an analgesic and sedative for wound care procedures in the pediatric patient with burns. J. Burn Care Rehabil. (1997) 18(1 Pt 1):34-36.
35. MARTYN JAJ, GREENBLATT DJ: Lorazepam conjugation unimpaired in burn patients. Anesthesiology (1985) 63:A113.
36. 1-antihistamines in children. Clin. Allergy Immunol. (2002) 17:437-464.
37. MERK HF: Standard treatment: the role of antihistamines. J. Investig. Dermatol. Symp. Proc. (2001) 6(2):153-156.
38. 2 antagonists. J. Burn Care Rehabil. (2001) 22(4):263-268.
39. KOPECKY EA, JACOBSON S, HUBLEY P, PALOZZI L, CLARKE HM, KOREN G: Safety and pharmacokinetics of EMLA in the treatment if postburn pruritus in pediatric patients: a pilot study. J. Burn Rehabil. (2001) 22(3):235-242.
40. WHITAKER C: The use of TENS for pruritus relief in the burns patient: an individual case report. J. Burn Care Rehabil. (2001) 22(4):274-276.
41. MATHESON JD, CLAYTON J, MULLER MJ: The reduction of itch during burn wound healing. J. Burn Care Rehabil (2001) 22(1):76-81.
42. DEMLING RH, DESANTI L: Topical doxepin cream is effective in relieving severe pruritus caused by burn injury: a preliminary study. Wounds (2001) 13(6):210-221.
43. 3 receptor antagonists versus traditional agents for the prophylaxis of postoperative nausea and vomiting. Can. J. Anaesth. (2000) 47(10):1008-1018.
44. ILECHUKWU ST: Psychiatry of the medically ill in the burn unit. Psychiatr. Clin. N. Am. (2002) 25(1):129-147.
45. DONNELLY CL, AMAYA-JACKSON L, MARCH JS: Psychopharmacology of pediatric posttraumatic stress disorder. J. Child Adolesc. Psychopharmacol. (1999) 9(3):203-220.
46. CYR M, FARRAR MK: Treatment for posttraumatic stress disorder. Ann. Pharmacother. (2000) 34(3):366-376.
47. ROBERT R, BLAKENEY PE, VILLARREAL C, ROSENBERG L, MEYER WJ 3rd: Imipramine treatment in pediatric burn patients with symptoms of acute stress disorder: a pilot study. J. Am. Acad. Child Adolesc. Psychiatry (1999) 38(7):873-882.
48. ROBERTS R, MEYER WJ 3rd, VILLAREAL C, BLAKENEY PE, DESAI M, HERNDON DN: An approach to the timely treatment of acute stress disorder. J. Burn Care Rehabil. (1999) 20(3):250-258.
49. STANOVIC JK, JAMES KA, VANDEVERE, CA. The effectiveness of risperidone on acute stress symptoms in adult burn patients: a preliminary retrospective pilot study. J. Burn Care Rehabil. (2001) 22(3):210-213.
50. ROSE M, SANFORD A, THOMAS C, OPP MR: Factors altering the sleep of burned children. Sleep (2001) 24(1):45-51.
51. BARRET JP, DARDANO AN, HEGGERS JP, MCCAULEY RL: Infestations and chronic infections in foreign pediatric patients with burns: is there a role for specific protocols? J. Burn Care Rehabil. (1999) 20:482-486.
52. HERNDON DN: Total Burn Care. 2nd Edn. WB Saunders, Philadelphia, PA, USA (2002):91.
53. HEGGERS JP, ROBSON MC: The emergence of silver sulphadiazine resistant Pseudomonas aeruginosa. Burns (1978) 5:184-187.
54. DESAI H, RUTAN RL, HEGGERS JP, HERNDON DN: Candida infection with and without nystatin prophylaxis. An 11-year experience with patients with burn injury. Arch. Surg. (1992) 127(2):159-162.
55. BARRET JP, RAMZY PI, HEGGERS JP, VILLAREAL C, HERNDON DN, DESAI MH: Topical nystatin powder in severe burns: a new treatment for angioinvasive fungal infections refractory to other topical and systemic agents. Burns (1999) 25(6):505-508.
56. HEGGERS JP, SAZY JA, STENBERG BD et al.: Bactericidal and wound healing properties of sodium hypochlorite. J. Burn Care Rehabil. (1991) 12:420-424.
57. DE GRACIA CG: An open study comparing topical silver sulfadiazine and topical silver sulfadiazine-cerium nitrate in the treatment of moderate and severe burns. Burns (2001) 27(1):67-74.
58. DEVECI M, ESKI M, SENGEZER M, KISA U: Effects of cerium nitrate bathing and prompt burn wound excision on IL-6 and TNF-α levels in burned rats. Burns (2000) 26(1):41-45.
59. ESKI M, DEVECI M, CELIKOZ B, NISANCI M, TUREGUN M: Treatment with cerium nitrate bathing modulate systemic leukocyte activation following burn injury: an experimental study in rat cremaster muscle flap. Burns (2001) 27(7):739-746.
60. DEMLING RH, LESLIE DESANTI MD: The rate of re-epithelialisation across meshed skin grafts is increased with exposure to silver. Burns (2002) 28(3):264-246.
61. WRIGHT JB, LAM K, BURET AG, OLSON ME, BURRELL RE: Early healing events in a porcine model of contaminated wounds: effects of nanocrystalline silver on matrix metalloproteinases, cell apoptosis, and healing. Wound Repair Regen. (2002) 10(3):141-151.
62. AL-HADDAD AM, UDO EE, MOKADAS EM, SANYAL SC, GRUBB WB: Persistence of a clone of methicillin-resistant Staphylococcus aureus in a burns unit. J. Med. Microbiol. (2001) 50(6):558-564.
63. YOWLER CJ, BLINKHORN RJ, FRATIANNE RB: Vancomycin-dependent enterococcal strains: case report and review. J. Trauma (2000) 48(4):783-785.
64. MOKADDAS EM, SANYAL SC: Resistance patterns of Pseudomonas aeruginosa to carbapenems and piperacillin/tazobactam. J. Chemother. (1999) 11(2):93-96.
65. MOKADDAS EM, SANYAL SC: Imipenem resistance in aerobic Gram-negative bacteria. J Chemother. (1998) 10(2):97-101.
66. REVATHI G, SHANNON KP. STAPLETON PD, JAIN BK, FRENCH GL: An outbreak of extended-spectrum, β-lactamase-producing Salmonella senftenberg in a burns ward. J. Hosp. Infect. (1998) 40(4):295-302.
67. GORDON KA, BEACH ML, BIEDENBACH DJ, JONES RN, RHOMBERG PR, MUTNICK AH: Antimicrobial susceptibility patterns of β-hemolytic and viridans group streptococci report from the SENTRY Antimicrobial Surveillance Program (1997-2000). Diagn. Microbiol. Infect. Dis. (2002) 43(2):157-162.
68. QUALE J, LANDMAN D, RAVISHANKAR J, FLORES C, BRATU S: Streptococcus pneumoniae, Brooklyn, New York: fluoroquinolone resistance at our doorstep. Emerg. Infect. Dis. (2002) 8(6):594-597.
69. KIMURA A, MOCHIZUKI T, NISHIZAWA K, MASHIKO K, YAMAMOTO Y, OTSUKA T: Trimethoprim-sulfamethoxazole for the prevention of methicillin-resistant Staphylococcus aureus pneumonia in severely burned patients. J. Trauma (1998) 45(2):383-387.
70. HEGGERS JP, MCCOY L, REISNER B, SMITH M, EDGAR P, RAMIREZ RJ: Alternate antimicrobial therapy for vancomycin-resistant enterococci burn wound infections. J. Burn Care Rehabil. (1998) 19(5):399-403.
71. SELMANPAKOGLU AN, CETIN C, SAYAL A, ISIMER A: Trace element (Al, Se, Zn, Cu) levels in serum, urine and tissues of burn patients. Burns (1994) 20(2):99-103.
72. BERGER MM, CAVADINI C, BART A et al.: Cutaneous copper and zinc losses in burns. Burns (1992) 18(5):373-380.
73. BOOSALIS MG, SOLEM LD, CERRA FB et al.: Increased urinary zinc excretion after thermal injury. J. Lab. Clin. Med. (1991) 118(6):538-545.
74. VAN RIJ AM, HALL MT, BRAY JT, PORIES WJ: Zinc as an integral component of the metabolic response to trauma. Surg. Gynecol. Obstet. (1981) 153(5):677-682.
75. KLEIN GL, HERNDON DN, GOODMAN WG et al.: Histomorphometric and biochemical characterization of bone following acute severe burns in children. Bone (1995) 17(5):455-460.
76. KEEN CL, GERSHWIN ME: Zinc deficiency and immune function. Ann. Rev. Nutr (1990) 10:415-431.
77. CUNNINGHAM JJ, LYDON MK, EMERSON R, HARMATZ R: Low caeruloplasmin levels during recovery from major burn injury: influence of open wound size and copper supplementation. Nutrition (1996) 12(2):83-88.
78. BOOSALIS MG, SOLEM LD, AHRENHOLZ DH, MCCALL JT, MCCLAIN J: Serum and urinary selenium levels in thermal injury. Burns Incl. Therm. Inj. (1986) 12(4):236-240.
79. KLEIN GL, HERNDON DN, RUTAN TC, MILLER NL, ALFREY AC: Elevated serum aluminum levels in severely burned patients who are receiving large quantities of albumin. J. Burn Care Rehabil, (1990) 11(6):526-530.
80. KLEIN GL, HERNDON DN, RUTAN TC, BARNETT JR, MILLER NL, ALFREY AC: Risk of aluminum accumulation in patients with burns and ways to reduce it. J. Burn Care Rehabil. (1994) 15(4):354-358.
81. KUROIWA K, NELSON JL, BOYCE ST, ALEXANDER JW, OGLE CK, INOUE S: Metabolic and immune effect of vitamin E supplementation after burn. J. Parenter. Enteral Nutr. (1991) 15(1):22-26.
82. TANAKA H, MATSUDA T, MIYAGANTANI Y, YUKIOKA T, MATSUDA H, SHIMAZAKI S: Reduction of resuscitation fluid volumes in severely burned patients using ascorbic acid administration: a randomized, prospective studv. Arch. Surg. (2000) 135(3):326-331.
83. NELSON JL, ALEXANDER JW, JACOBS PA, ING RD, OGLE CK: Metabolic and immune effects of enteral ascorbic acid after burn trauma. Burns (1992) 18(2):92-97.
84. TRYBA M: Role of acid suppressants in intensive care medicine. Best Pract. Res. Clin. Gastroenterol. (2001) 15(3):447-461.
85. HEYLAND DK, DROVER JW, DHALIWAL R, GREENWOOD J: Optimizing the benefits and minimizing the risks of enteral nutrition in the critically ill: role of small bowel feeding. J. Parenter. Enteral Nutr. (2002) 26(6 Suppl.):S51-S57.
86. WAHL WL, BRANDT MM: Potential risk factors for deep venous thrombosis in burn patients. J. Burn Care Rehabil. (2001) 22(2):128-131.
87. HARRINGTON DT, MOZINGO DW, CANCIO L, BIRD P, JORDAN B, GOODWIN CW. Thermally injured patients are at significant risk for thromboembolic complications. J. Trauma (2001) 50(3):495-499.
88. HERNDON DN, THOMPSON PB, TRABER DL et al.: Diagnosis, Pathophysiology and treatment of inhalation injury: the art and science of burn care. Baltimore University Press (1987).
89. DESAI MH, MLCAK R, RICHARDSON J, NICHOLS R, HERNDON DN: Reduction in mortality in pediatric patients with inhalation injury with aerosolized heparin/N-acetylcysteine therapy. J. Burn Care Rehabil. (1998) 19(3):210-212.
90. HERNDON DN, TRABER DL, NIEHAUS GD et al.: The pathophysiology of smoke inhalation in a sheep model. J. Trauma (1984) 24:1044-1051.
91. SAFIRSTEIN R, ANDRADE L, VEIRA JM: Acetylcysteine and nephrotoxic effects of radiographic contrast agents - a new use for an old drug. N. Engl. J. Med. (2000) 343:210.
92. HERNDON DN: Total Burn Care. 2nd edn. WB Saunders, Philadelphia, PA, USA (2002):6.
93. ROSE JK, HERNDON DN: Advances in the treatment of burn patients. Burns (1997) 23(Suppl. 1):S19-S26.
94. HERNDON DN, HART, DW, WOLF SE et al.: Reversal of catabolism by β-blockade after severe burns. N. Engl. J. Med. (2001) 345:1223-1229.
95. HART DW, WOLF SE, MLCAK RP et al.: Persistence of muscle catabolism after severe burn. Surgery (2000) 128:312-319.
96. WILMORE DW, LONG JM, MASON AD et al.: Catecholamines: mediator of the hypermetabolic response to thermal injury. Ann. Surg. (1974) 180:653-669.
97. WOLF SE, BARROW RE, HERNDON DN: Growth hormone and IGF-I therapy in the hypercatabolic patient. Baill Clin. Endocrinol. Metabol. (1996) 10(3):447-463.
98. PIERRE E, BARROW R, HAWKINS H et al.: Effects of insulin on wound healing. J. Trauma (1998) 44:342-345.
99. 3 treatment. Ann. Surg. (1999) 229(5):713-720.
100. FERRANDO AA, SHEFFIELD-MOORE M, WOLF SE, HERNDON DN, WOLFE RR: Testosterone administration in severe burns ameliorates muscle catabolism. Crit. Care Med. (2001) 29:1936-1942.
101. HART DW, WOLF SE, RAMZY PI et al.: Anabolic effects of oxandrolone after severe burn. Ann. Surg. (2001) 233(4):556-564.
102. BREITENSTEIN E, CHIOLERO RL, JEQUIER E et al.: Effects of β-blockade on energy metabolism following burns. Burns (1990) 16:259-264.
103. HART DW, WOLF SE, CHINKES DL, WOLFE RR: Anabolic strategies after severe burn. J. Am. Coll. Surg. (In Press).
104. HERNDON DN, BARROW RE, KUNKEL KR et al.: Effects of recombinant human growth hormone on donor healing time in severely burned children. Ann. Surg. (1990) 212:424-431.
105. GILPIN DA, BARROW RE, RUTAN RL, BROEMELING L, HERNDON D: Recombinant human growth hormone accelerates wound healing in children with large cutaneous burns. Ann. Surg. (1994) 220(1):19-24.
106. RAMIREZ RJ, WOLF SE, BARROW RE, HERNDON DN: Growth hormone treatment in pediatric burns: a safe therapeutic approach. Ann. Surg. (1998) 228:439-448.
107. KLEIN GL, WOLF SE, GOODMAN WG, PHILLIPS WA, HERNDON DN: The management of acute bone loss in severe catabolism due to burn injury. Horm. Res. (1997) 48:83-87.
108. FERRANDO AA, CHINKES DL, WOLF SE, MATIN S, HERNDON DN, WOLFE RR: A submaximal dose of insulin promotes net skeletal muscle protein synthesis in patients with severe burns. Ann. Surg. (1999) 229:11-18.
109. SHEFFIELD-MOORE M, URBAN RJ, et al.: Short-term oxandrolone administration stimulates net muscle protein synthesis in young men. J. Clin. Endocrinol. Metab. (999) 84:2705-2711.
110. HERNDON DN, HART DW, WOLF SE, CHINKES DL, WOLFE RR: Reversal of catabolism by β-blockade after severe burns. N. Engl. J. Med. (2001) 345(17):1223-1229.
111. MINIFEE PK, BARROW RE, ABSTON S, DESAI MH, HERNDON DN: Improved myocardial oxygen utilization following propranolol infusion in adolescents with postburn hypermetabolism. J. Ped. Surg. (1989) 24:806-811.
112. HERNDON DN, HART DW, WOLF SE, CHINKES DL, WOLFE RR: Reversal of catabolism by β-blockade after severe burns. N. Engl. J. Med. (2001) 345(17):1223-1229.
113. 1 blockade decreases cardiac work without affecting protein breakdown or lipolysis in severely burned patients. Surg. Forum (1993) 44:25-27.
114. AARSLAND A, CHINKES D, WOLFE RR et al.: β-blockade lowers peripheral lipolysis in burn patients receiving growth hormone. Ann. Surg. (1996) 233(6):777-789.
115. RUTAN RL, HERNDON DN: Growth delay in postburn pediatric patients. Arch. Surg. (1990) 125:392-395.